UROVANT SCIENCES INC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.2M
Doctors Paid
9,422
Transactions
38,771
2022 Total
$7.2M
Payment Breakdown by Category
Research$7.0M (75.6%)
Food & Beverage$767,926 (8.3%)
Consulting$305,443 (3.3%)
Travel$232,117 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.0M | 1,070 | 75.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $924,862 | 502 | 10.0% |
| Food and Beverage | $767,926 | 35,981 | 8.3% |
| Consulting Fee | $305,443 | 158 | 3.3% |
| Travel and Lodging | $232,117 | 963 | 2.5% |
| Space rental or facility fees (teaching hospital only) | $8,000 | 2 | 0.1% |
| Education | $3,430 | 90 | 0.0% |
| Honoraria | $2,448 | 5 | 0.0% |
Payments by Type
Research
$7.0M
1,070 transactions
General
$2.2M
37,701 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | $4.6M | 0 | 455 |
| Composur, A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder | $700,844 | 0 | 251 |
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | $490,024 | 0 | 110 |
| An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence | $468,080 | 0 | 225 |
| AnOpen-Label, Randomized, Crossover, Single Dose Study to Assess thePharmacokinetics and Safety of Vibegron TabletandGranuleFormulations | $426,237 | 0 | 13 |
| An open-label, randomized, croosover, single dose study to assess the pharmacokinetics and saftey of vibegron tablet and granule formulations | $230,828 | 0 | 11 |
| A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) | $7,500 | 0 | 1 |
| A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) (Empowur) | $5,000 | 0 | 1 |
| Composur | $1,976 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Diane Newman, Crnp, CRNP | Adult Health | Philadelphia, PA | $132,363 | $0 |
| David Staskin, Md, MD | Urology | Brighton, MA | $113,335 | $0 |
| Dr. Matt Rosenberg, M.d, M.D | Family Medicine | Jackson, MI | $88,793 | $0 |
| Scott Macdiarmid, Md, MD | Urology | Greensboro, NC | $73,701 | $0 |
| Michael Kennelly, Md, MD | Urogynecology and Reconstructive Pelvic Surgery | Charlotte, NC | $66,484 | $0 |
| Dr. Jeffrey Frankel, M.d, M.D | Neurology | East Orange, NJ | $62,536 | $0 |
| Dr. Phillip Ginsberg, D.o, D.O | Specialist | Philadelphia, PA | $62,044 | $0 |
| Elizabeth Coon-Nguyen, Md, MD | Family Medicine | Kingwood, TX | $52,302 | $0 |
| Meenakshi Patel, Md, MD | Geriatric Medicine | Centerville, OH | $50,732 | $0 |
| Mr. Manuel Suarez Barcelo, Md, MD | Internal Medicine | North Miami, FL | $46,033 | $0 |
| Dr. Laura Giusto, M.d, M.D | Urology | Owings Mills, MD | $41,836 | $0 |
| Stephen Kraus, Md, MD | Urology | San Antonio, TX | $39,226 | $0 |
| Andrew Offerle, M.d, M.D | General Practice | Fort Wayne, IN | $35,478 | $0 |
| Dr. Ashley Tapscott, D.o, D.O | Urology | Nashville, TN | $28,205 | $0 |
| Eric Rovner, Md, MD | Urology | Charleston, SC | $27,108 | $0 |
| Peter Sand, M.d, M.D | Urogynecology and Reconstructive Pelvic Surgery | Skokie, IL | $26,915 | $0 |
| Dr. Rena Malik, M.d, M.D | Urology | Newport Beach, CA | $26,479 | $0 |
| Dr. Nathaniel Barnes, M.d, M.D | Urology | Webster, TX | $26,374 | $0 |
| Alexandra Rogers, Md, MD | Urology | Lafayette, CO | $22,555 | $0 |
| Lily Arya, Md, MD | Obstetrics & Gynecology | Philadelphia, PA | $19,806 | $0 |
| David Sussman, D.o, D.O | Urology | Linwood, NJ | $19,762 | $0 |
| Dr. Jeffrey Deitch, Do, DO | Family Medicine | Sterling Heights, MI | $18,943 | $0 |
| Dr. Richard Stefanacci, Do, DO | Geriatric Medicine | Philadelphia, PA | $18,023 | $0 |
| Dr. Benjamin Brucker, Md, MD | Urology | New York, NY | $17,952 | $0 |
| Mrs. Melissa Blackburn-Kierkla, Np, NP | Pediatrics | Monson, MA | $17,201 | $0 |
About UROVANT SCIENCES INC
UROVANT SCIENCES INC has made $9.2M in payments to 9,422 healthcare providers, recorded across 38,771 transactions in the CMS Open Payments database. In 2022, the company paid $7.2M. The top product by payment volume is GEMTESA ($8.7M).
Payments were distributed across 123 medical specialties. The top specialty by payment amount is Urology ($899,546 to 3,135 doctors).
Payment categories include: Food & Beverage ($767,926), Consulting ($305,443), Research ($7.0M), Travel & Lodging ($232,117).
UROVANT SCIENCES INC is associated with 1 products in the CMS Open Payments database.